Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 20, 2019 07:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Announces Publication of NurOwn® ALS Phase 2 Randomized Clinical Trial Data in Neurology

A single transplantation of MSC-NTF cells (NurOwn®) in ALS clinical trial participants met the primary safety endpoint and demonstrated promising stabilization of ALS disease progression of up to...
November 14, 2019 07:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Announces Research Grant Award From the National Multiple Sclerosis Society

NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that...
November 14, 2019 06:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update

Conference Call and Webcast Today at 8:00 a.m. Eastern Time Highlights Include: ALS Phase 3 Clinical Trial Fully Enrolled, Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial...
November 13, 2019 05:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Announces Grant of a New Japanese Patent for NurOwn®

NEW YORK, Nov. 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that...
November 12, 2019 01:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting

NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
November 05, 2019 06:15 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Comprehensive Corporate Update

NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
October 28, 2019 07:45 ET | Source: BrainStorm Cell Therapeutics Inc.

NurOwn® Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue

NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
October 25, 2019 01:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
October 24, 2019 08:45 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics’ President and CEO to be Featured as Keynote Speaker at Cell Series UK 2019

NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
October 23, 2019 01:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Presentations at Neuromuscular Drug Development Summit

NEW YORK, Oct. 23, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...